Coway Announces Financial Results for Q4 and FY2024

Coway Announces Financial Results for Q4 and FY2024

Coway's 2024 Q4 revenue reached KRW 1,125.7 billion (+12.1% YoY) with an operating profit amounted to KRW 183.4 billion (+10.4% YoY) The company's FY2024 annual revenue totaled KRW 4,310.1 billion (+8.7% YoY) with an operating profit of KRW 795.4...

Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases

Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases

HONG KONG, Feb. 14, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for...

Arcadium Lithium Receives All Required Regulatory Approvals Globally to Close Acquisition by Rio Tinto and Announces Court Hearing Date

Arcadium Lithium Receives All Required Regulatory Approvals Globally to Close Acquisition by Rio Tinto and Announces Court Hearing Date

PHILADELPHIA and PERTH, Australia, Feb. 14, 2025 /PRNewswire/ -- Arcadium Lithium plc (NYSE: ALTM, ASX: LTM, "Arcadium Lithium"), a leading global lithium chemicals producer, has now received all required pre-closing regulatory approvals in...

Bellevue Life Sciences Acquisition Corp. Announces Approval of Business Combination Proposal And Name Change to OSR Holdings, Inc.

Bellevue Life Sciences Acquisition Corp. Announces Approval of Business Combination Proposal And Name Change to OSR Holdings, Inc.

SEOUL, South Korea, Feb. 14, 2025 /PRNewswire/ -- Bellevue Life Sciences Acquisition Corp. ("BLAC") announced today the approval of each of the proposals presented at the special meeting of its stockholders (the "Special Meeting") held today,...

O-RAN ALLIANCE Announces Global PlugFest Spring 2025 to Further Accelerate the Maturity of O-RAN Products and Solutions

O-RAN ALLIANCE Announces Global PlugFest Spring 2025 to Further Accelerate the Maturity of O-RAN Products and Solutions

O-RAN ALLIANCE calls for participation in the O-RAN Global PlugFest Spring 2025 with 23 hosts in 18 labs around the world O-RAN ALLIANCE invites any of its Members and Participants to join the PlugFest and benefit from well-organized testing and...

JOICO© ANNOUNCES KATE HUDSON AS FIRST-EVER GLOBAL CELEBRITY SPOKESPERSON

JOICO© ANNOUNCES KATE HUDSON AS FIRST-EVER GLOBAL CELEBRITY SPOKESPERSON

LOS ANGELES, Feb. 13, 2025 /PRNewswire/ -- Joico, known for its legacy of product performance and the joi (e) de vivre they bring to hair enthusiasts around the world, is celebrating an incredible milestone: 50 years of healthy hair innovations....

Conrad Xiamen Awarded Four-Star Recognition in the 2025 Forbes Travel Guide

Conrad Xiamen Awarded Four-Star Recognition in the 2025 Forbes Travel Guide

The Only Forbes-Starred Hotel in Xiamen XIAMEN, China, Feb. 13, 2025 /PRNewswire/ -- Conrad Xiamen proudly announces its Four-Star recognition in the 2025 Forbes Travel Guide, making it the only hotel in Xiamen to receive this prestigious accolade....

Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101

Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases,...

Databricks Announces Launch of SAP Databricks

Databricks Announces Launch of SAP Databricks

Databricks announces new product natively integrated into the SAP Business Data Cloud SAN FRANCISCO, Feb. 13, 2025 /PRNewswire/ -- Databricks, the Data and AI company, today announced the launch of SAP Databricks, a strategic product and...

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM). After the mainland of China, South Korea, Australia and Singapore, Taiwan market is the fifth APAC market...

  • 1
  • ...
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • ...
  • 48
  • menu
    menu